The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA)

Not Applicable

• Conditions: Bone Density; Arthroplasty, Replacement, Hip
• Interventions: Drug: alendronate, alfacalcidol

• Registration Number: NCT01020253
• Lead Sponsor: Yokohama City University Medical Center

Brief Summary

The purpose of this study is to evaluate whether alendronate and alfacalcidol are effective on prosthetic or lumbar spine BMD after total hip arthroplasty.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01
• Primary Completion: 2008-04
• Study First Submitted: 2009-11-24
• Study First Submitted QC: 2009-11-24
• Study First Posted: 2009-11-25
• Status Verified: 2009-12
• Last Update Submitted: 2009-12-02
• Last Update Posted: 2009-12-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• osteoarthritis of the hip
• patients after total hip arthroplasty

Exclusion Criteria

• diseases related to bone metabolism
• patients taking drugs which affect bone metabolism

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Alfacalcidol medication	alendronate, alfacalcidol	-
Non-medication	alendronate, alfacalcidol	-
Alendronate medication	alendronate, alfacalcidol	-

Primary Outcome Measures

Name	Time	Method
DEXA QDR 2000, Hologic Co.	1, 12, 24 and 48 weeks after operation

Trial Locations

Locations (1)

Department of orthopaedic surgery, Yokohama City University; 🇯🇵 Yokohama, Kanagawa, Japan